

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/562,990	03/12/2007	Ettore Tallia	1011-784	3630
47888 7590 07/06/2009 HEDMAN & COSTIGAN P.C. 1185 AVENUE OF THE AMERICAS			EXAMINER	
			KOSINSKI, IRINA Y	
NEW YORK, NY 10036			ART UNIT	PAPER NUMBER
			4131	
			MAIL DATE	DELIVERY MODE
			07/06/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/562 990 TALLIA, ETTORE Office Action Summary Art Unit Examiner IRINA KOSINSKI 4131 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 28 April 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-10 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-3 is/are rejected. 7) Claim(s) 4-10 is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date 12/27/2005

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/562,990 Page 2

Art Unit: 4131

DETAILED ACTION

Applicant's response of 05/22/2009 to the Election of Species is acknowledged. Applicant elected, with traverse species of group 1, namely oil phase comprising vegetable oils, corresponding to claims 1 and 6-10. Applicant is traversing on the grounds that a Markush group, representing oils has a common property, such as the use as a mouthwash, and therefor, the division should not be required. Upon further consideration, the Election of Species requirement is withdrawn. Claims 1-10 are under consideration.

Information Disclosure Statement

 The information disclosure statement (IDS) submitted on 12/27/2005 was filed by the applicant. The submission is in compliance with the provisions of 37 CFR 1.97.
Accordingly, the information disclosure statement is being considered by the examiner.

Claim Objections

Claims 4-10 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer to other claims in the alternative only. See MPEP § 608.01(n). Accordingly, the claims 4-10 have not been further treated on the merits.

Claim Rejections - 35 USC § 102(b)

 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. Application/Control Number: 10/562,990

Art Unit: 4131

 Claims 1-3 are rejected under 35 U.S.C. 102(b) as being anticipated by Pianotti (EP 0244363 A1).

- Pianotti discloses an antimicrobial composition in a form of a mouthwash comprising an oil phase containing water-insoluble antiseptic substances (thymol, eucaliptol, methyl salicylate, menthol), water, and water soluble antibacteric substances (chlorhexidine digluconate) (example 4).
- 4. The mixture of essential oils varies from about 0.05% to about 10% by weight (claim 4), see example 4 for the ranges of ingredients specified in the instant claim 3 (from 60%w/w to about 95%w/w).

Obvious-Type Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Omum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422

Application/Control Number: 10/562,990

Art Unit: 4131

F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-2 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2 of a copending Application #11500253.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims have overlapping subject matter.

Claim 1 of the copending application discloses an antibacteric composition to be used as a toothpaste, comprising antiseptic substances and further comprising an oil phase. Claim 2 of the copending application discloses that the composition according to claim 1 also comprises an aqueous phase, in which antibacteric substances are dissolved, and an emulsion.

The copending claims are obvious over one another because they both encompass an antibacterial composition comprising an oil-in-water emulsion, where Application/Control Number: 10/562,990

Art Unit: 4131

antiseptic substances are dissolved in the oil phase, and antibacteric substances are dissolved in the water phase. The difference between the claims is such that the copending claims disclose that the composition can be used in a toothpaste, while the instant claims disclose it's use in a mouthwash.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

5. Claims 1-10 are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to IRINA KOSINSKI whose telephone number is (571)270-1334. The examiner can normally be reached on Monday through Friday 7:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Patrick Nolan can be reached on (571)272-0847. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/562,990 Page 6

Art Unit: 4131

/IRINA KOSINSKI/ Examiner, Art Unit 4131

/Patrick J. Nolan/ Supervisory Patent Examiner, Art Unit 4131